Kornimate/medical-research-clean huggingface dataset:
registry evaluating af ablation techniques

Conditions: Atrial Fibrillation; Catheter Ablation

Summary: the purpose of this observational registry is to prospectively collect procedure efficiency, safety and acute and long term outcome data from catheter ablation procedures as treatment of paroxysmal atrial fibrillation, using the following treatment modalities: * cryoballoon ablation * manual guided rf ablation using contact force catheters * remote magnetic navigation guided rf ablation with e-contact and high power settings * remote magnetic navigation guided rf ablation with e-contact and low power settings


Eligibility criteria:
inclusion criteria: * documented paroxysmal atrial fibrillation * eligibility for pulmonary vein isolation by catheter ablation based on the respective acc/aha/esc guideline valid at the date of procedure * signed the informed consent to participate in the registry exclusion criteria: * younger than 18 years of age * prior af ablation procedure (including maze procedure) * prior ablation of non-af arrhythmia within 3 months of enrollment * presence of cardiac thrombus * other af ablations performed during procedure (e.g. lines, rotor, cfae's etc) * active endocarditis or systemic infection * life expectancy \< 1 year * pregnancy

Keywords: paroxysmal atrial fibrillation catheter ablation cryoballoon radiofrequency ablation remote magnetic navigation
current status of btki treatment for cll/sll in china

Conditions: CLL/SLL

Summary: btki has become the standard treatment regimen for cll/sll，there is a lack of large-scale real-world studies on the use status and related influencing factors of btk inhibitors. therefore, we plan to conduct this multicenter retrospective cross-sectional study to understand the current situation of btk inhibitor treatment for cll/sll patients in china and the related influencing factors, and to explore more suitable treatment patterns based on this.


Eligibility criteria:
inclusion criteria: * age ≥ 18 years; * patients with a confirmed diagnosis of cll/sll; * received btk inhibitor treatment between february 2023 and february 2024. exclusion criteria: * patients with other types of lymphoma; * cases deemed unsuitable for inclusion in this study by the investigators.
compassionate use of omegaven® in the treatment of parenteral nutrition induced hepatic injury

Conditions: Cancer; Hepatic Injury

Summary: the purposes of this study are to make omegaven® available to cancer patients with liver disease and to determine if omegaven® can improve or prevent further liver disease. the study will also look at the effects omegaven® has on immune function.

this compassionate use study will include patients with advanced cancer requiring pn for long-term nutrition support who have developed pn-induced hepatic injury or who have existing hepatic dysfunction. therapy with omegaven will be provided at an initial dose of 0.1 g/kg body weight (1ml/kg) and increased to 0.2 g/kg body weight (2ml/kg) on day 2 or 3 of treatment. for patients \> 120% ideal body weight, adjusted body weight will be used. the infusion rate will not exceed 0.5ml omegaven/kg body weight/hr (corresponding to 0.05g fish oil/kg/hr). omegaven will be co-administered via a y-site infusion, with containers being changed every 12 hours. the patient may receive other lipids to meet essential fatty acid (efa) and/or additional calorie needs. patients will receive the initial infusion of pn containing omegaven at midwestern regional medical center (mrmc) in the infusion center to observe for adverse reactions. if an adverse reaction is observed, iv steroids \& benadryl will be administered \& omegaven will be discontinued. patients will continue to receive infusions at ctca for the first 2 to 3 days of dosing. after tolerance is established, patients will receive treatment at home with coram. all study patients will have a screening visit; day 1, day 2 and day 3 visits; and weekly visits for one month (see table 2).

Eligibility criteria:
inclusion criteria: 1. male or female; ages 18 to 80 years old 2. receiving treatment at cancer treatment centers of america 3. receiving pn (either in the infusion center or at home) 4. have existing hepatic dysfunction defined as elevation of \> 3x the normal level of one or more of the following:alkaline phosphatase (alp), aspartate aminotransferase (ast), or alanine aminotransferase alt) and/or bilirubin \> 2 mg/dl in the absence of biliary obstruction 5. able to provide informed written consent exclusion criteria: 1. hypertriglyceridemia (triglycerides \[tg\] \> 400) 2. allergy to fish or egg protein 3. currently on therapeutic doses of coumadin, heparin, or low molecular eight heparin 4. hemodynamically unstable 5. bilirubin \> 5 mg/dl 6. documented liver metastases 7. unstable diabetes with known diabetic ketoacidosis within 7 days of screening 8. recent cardiac infarction (within 6 months) and taking plavix 9. severe hemorrhagic disorders 10. current anticoagulation therapy for deep venous thromboembolism or pulmonary embolism 11. active sepsis 12. undefined coma status 13. in patients with abnormal kidney function, renal insufficiency with calculated creatinine clearance \< 30 ml/min 14. pregnancy or lactation
pulmicort asthma prevention (post-pac)

Conditions: Asthma

Summary: this prospective study will evaluate the feasibility of the defined decision tree for the treatment of asthmatic young children. children who develop episode (=3 consecutive days) of any troublesome lower respiratory symptoms are treated according to a strictly pre-defined multi-steps treatment algorithm until the age of 6 years.


Eligibility criteria:
inclusion criteria: * children form the copsac/pac study with episodes of troublesome respiratory symptoms. episodes are defined as 3 consecutive days of any troublesome lower respiratory symptoms. exclusion criteria: * differential diagnoses including at least a chest x-ray and sweat test.

Keywords: children of asthmatic mothers
jet injectors versus conventional anesthetic technique in children

Conditions: Anesthesia

Summary: this clinical study was conducted to compare the needleless comfort-in jet injector device and the conventional needle technique in terms of 1. pain level during the administration of local anesthesia in children. 2. their effectiveness during pulpotomy procedures in primary molars. whether comfort-in jet injector device will achieve sufficient anesthesia for the procedures undertaken during pulpotomy or not when compared to the conventional technique and the pain levels of both techniques during the anesthesia step.

cooperative healthy seventy-six children required pulpotomy treatment in primary molars aged 4 to 7 years with no previous dental local anesthetic experience, were recruited from the pediatric dental clinic, faculty of dentistry, mansoura university. the patients' behavior was categorized as positive or definitely positive according to frankl behavior scale. all children were divided randomly into two main groups (38 each), control group i (conventional needle) and experimental group ii (comfort-in). then two sub-group were constructed, each consists of 19 children. sub-group i a and ii a (ianb) and sub-group i b and ii b (maxillary infiltration), the chief complaint of the child was the main determinant for the side (right or left) to be injected. the jet injector technique was applied in 2 shots with (0.5 ml) each, to unify the dose with the conventional technique. after testing the anesthesia's profoundness, pulpotomy steps proceeded. pain evaluation was set up according to two different subjective and objective scales, the wbfp and flacc scales. all parents of the children included in this study answered a post-treatment questionnaire to measure the degree of satisfaction regarding the technique that was selected for his/her child. data were collected, tabulated, and statistically analyzed.

Eligibility criteria:
inclusion criteria: 1. children who require local anesthetic injection for pulpotomy. 2. cooperative children (positive or definitely positive on frankel's scale). 3. children who had no previous dental local anesthetic experience, to avoid the influence of a negative or positive memory. 4. children who have been determined to be healthy and free of systemic diseases. 5. children who do not have any contraindications for administering a local anesthetic agent. exclusion criteria: 1. children suffering from medical illness, neurosensory disturbances, and psychiatric disorders. 2. children who could not comprehend the pain measures. 3. children with emergencies and acute dental conditions.

Keywords: jet injector needle comfort-in pain perception needleless pediatric dentistry
characteristic of drug users chronic wound

Conditions: Wound; Drug Use

Summary: the aim of this study is to describe demographic, clinical, etiological characteristic and evolution of drug addict's chronic wounds .


Eligibility criteria:
inclusion criteria: * all drug addict with chronic wound ( evolving at least since 1 month) exclusion criteria: * use following medication inductor of cutaneous ulcer: hydroxycarbamide, gefitinib, cetuximab, sunitinib, sorafenib, pazopanib, gemcitabine, sirolimus, methotrexate, nicorandil .
study comparing the p200te and the p200txe in glaucoma patients

Conditions: Glaucoma

Summary: the study evaluates the image quality between two oct devices.

the objective of this study is to collect oct scans to compare the qualitative b scan images produced by the p200txe to the p200te device in glaucoma subjects.

Eligibility criteria:
inclusion criteria: * male or female subjects 22 years of age or older who have full legal capacity to volunteer on the date the informed consent is signed; * subjects who can follow the instructions by the clinical staff at the clinical site, * subjects who agree to participate in the study; * subjects who have been diagnosed with glaucoma in the study eye as confirmed by the investigator; exclusion criteria: * subjects unable to tolerate ophthalmic imaging; * subjects with ocular media not sufficiently clear to obtain acceptable oct images; * subjects with any clinically significant ocular pathology except glaucoma, as determined by self-report and/or investigator assessment on the day of the study visit; * subjects who are not reliably tested with at least one humphrey field analyzer (hfa) visual field (24-2 or 30-2, white on white) measured on the day of the study visit or within the previous year from the study visit, defined as fixation losses \> 20% or false positives \> 33%, or false negatives \> 33%; * subjects with history of dementia or multiple sclerosis
inspiratory muscle strength training in post-covid syndrome

Conditions: Cardiovascular Abnormalities; Post-COVID-19 Syndrome; Physical Exercise

Summary: patients with post-covid-19 syndrome are at high risk of developing cardiovascular diseases 12 months after acute infection of covid-19. we recently revealed that these patients have elevated muscular sympathetic nerve activity (msna), vascular dysfunction, impaired cardiac diastolic function, and reduced functional capacity. considering that these outcomes are independent predictors of cardiovascular mortality, it is urgent to restore the cardiovascular health of these patients. high resistance inspiratory muscle strength training (imst) at 75% of pressure inspiratory (pimax) performed at home (5 min/session, 5-7 times/week per 6 weeks) reduces the msna, improves the endothelial function and lowers blood pressure in different populations. based on these findings, imst (75% pimax) is an excellent therapeutic option for patients with post-covid-19 syndrome. therefore, the aim of the present proposal is to test whether imst (75% pimax) reduces sympathetic activity, improves vascular function, and restores cardiac function, evoking an increase in functional capacity in patients with post-covid-19 syndrome. to test these hypotheses we will conduct a randomized, double-blind, sham-controlled clinical trial to test these hypotheses.


Eligibility criteria:
inclusion criteria: * post-covid-19 syndrome * have been diagnosed with covid-19 by rt-pcr * have oxygen saturation ≤ 93% in room air during the acute phase of the covid-19 * have received oxygen supply from any device during the acute phase of the covid-19 * hospitalization to treat the covid-19 * participants in cardiopulmonary rehabilitation or physical conditioning programs exclusion criteria: * pregnant * history of chronic obstructive pulmonary disease or dependence on oxygen support * history of cardiovascular and renal diseases and cancer prior to the covid-19 diagnosis * difficulties in moving to the laboratory for assessments
tenofovir alafenamide versus entecavir for the treatment of chronic hepatitis b

Conditions: Hepatitis B; Viral Hepatitis

Summary: to compare the efficacy and renal safety of tenofovir alafenamide (taf) versus entecavir (etv) in the chronic hepatitis b patients.

with high antiviral potency and low drug resistance rate, both etv and tenofovir disoproxil fumarate (tdf) have been recommended as the first-line antiviral therapy for chronic hepatitis b (chb). however, risk of renal dysfunction remains an issue in tdf long-term therapy. tenofovir alafenamide (taf) is a novel prodrug of tenofovir and is formulated to deliver the active metabolite to target cells more efficiently than tdf at lower doses, thereby reducing systemic exposure to tenofovir. importantly, taf had improved renal safety as compared to tdf. taf has been approved for treating chb since 2017; however, it is still unknown whether the efficacy and renal safety of taf is compatible to those of etv. the investigators aim to conduct an open label, randomized controlled trial comparing taf with etv for assessing their efficacy and renal safety in chb patients. the eligible chb patients are randomly assigned (1:1) to receive taf or etv. after allocation to taf group or etv group, study subjects will receive therapy for 3 years (144 weeks).

Eligibility criteria:
inclusion criteria: 1. patients more than 20 years old 2. chronic hepatitis b patients 3. patients who were indicated for hepatitis b virus antiviral therapy exclusion criteria: 1. decompensated liver disease (child-pugh b \&c) 2. end stage renal disease (egrf \< 15 ml/min/1.73m2) 3. prior use of nucleot(s)ide analogues for chronic hepatitis b 4. prior use of interferon for chronic hepatitis b within six months 5. known history of human immunodeficiency virus or hepatitis c virus co-infection 6. concurrent other uncontrolled malignancy 7. women in pregnancy or lactation 8. cannot conform to the study protocol of this study

Keywords: hepatitis b viral hepatitis tenofovir alafenamide entecavir
patient-generated health data collection during chemoradiotherapy for lung cancer

Conditions: Thoracic Cancer

Summary: this is an observational study involving the collection of patient-generated health data using an apple watch, a home pulse oximeter, and a smartphone during a course of proton beam radiotherapy for lung cancer. the study period over which this information is collected will range from the day of study enrollment until two weeks after radiotherapy completion. subjects will complete a short satisfaction survey at the end of the study period. other information that is collected as part of routine care for this patient population will be extracted from subjects' medical records during the study period and afterwards.

this is an observational study involving the collection of patient-generated health data using an apple watch, a home pulse oximeter, and a smartphone during a course of proton beam radiotherapy for lung cancer. the study period over which this information is collected will range from the day of study enrollment until two weeks after radiotherapy completion. subjects will complete a short satisfaction survey at the end of the study period. other information that is collected as part of routine care for this patient population will be extracted from subjects' medical records during the study period and afterwards. primary objective • to demonstrate the feasibility of patient-generated health data collection during thoracic proton beam radiotherapy for lung cancer. secondary objective • to demonstrate the face validity of physical activity and vital sign data collected during proton beam radiotherapy for lung cancer. exploratory objective • to explore associations between radiotherapy treatment parameters, wearable device data, patient-reported outcomes, adverse events, and long-term clinical outcomes.

Eligibility criteria:
inclusion criteria: * plan for fractionated (≥15 treatments) proton beam thoracic radiotherapy with curative intent for lung cancer * non-small cell lung cancer (nsclc) or small cell lung cancer (sclc) histology is permitted. * concurrent chemotherapy is permitted but not required.. * previous thoracic radiotherapy is allowed. * ability to complete study surveys in english or spanish * age \>/= 18 * concurrent enrollment on other trials is permitted * patients who already use wearable devices and/or smartphones that monitor physical activity are eligible for this trial, provided they agree to utilize the devices provided by the study team during the study period * all patients must sign study-specific informed consent prior to study entry exclusion criteria: * ongoing treatment for another cancer that is expected to affect the toxicity profile of thoracic radiotherapy * pregnancy or women of childbearing potential and men who are sexually active and not willing/able to use medically acceptable forms of contraception; this exclusion is necessary because the treatment involved in this study may be significantly teratogenic
predictive factors of regain in bariatric patients without outpatients care regular.

Conditions: Obesity; Bariatric Surgery

Summary: the bariatric surgery is recommended for treatment of patients with severe obesity, resulting in greater weight loss and improvement of cardiovascular and metabolic comorbidities. however, weight regain is observed in patients after surgery, leading to health adverse outcomes. the purpose of this study is to identify the rate of weight regain and predictive factors of regain in bariatric patients without outpatients care regular.

post-bariatric patients without care by health professional will be recruited. patients will be divided, initially, in two groups by time after surgical procedure, as follows: group 1≤ (g1≤) - patients that performed bariatric surgery for ≤ 1 year and group 1\> (g1\>) - patients that performed bariatric surgery for \> 1 year. patients will be seen in a medical set for the first time at the policlínica piquet carneiro (ppc) for outpatients care, which will consist of anamnesis and physical examination, obtaining demographic, socioeconomic data, medications and clinical history. the txr will be calculated by \[txr = (current weight - minimum weight reported) x 100 / (weight preoperatively reported - minimum weight related)\] and information on predictive variables for weight regain will be obtained by alcohol use disorders identification test (audit), beck depression inventory (bdi), international physical activity questionnaire (ipaq), actigraph gt3x + accelerometer, 36-item short-form health survey (sf-36), eating disorder examination-questionnaire (ede-q) and repetitive eating questionnaire (rep(eat) q). the inclusion period of new patients in the ppc obesity clinic will be one year.

Eligibility criteria:
inclusion criteria: - bariatric patients without regular medical follow-up exclusion criteria: * pregnancy * bariatric patients under one year of surgery

Keywords: obesity bariatric surgery weight gain predictive factors
age-related changes and cycloplegia-induced differences in the human crystalline lens

Conditions: Cataract

Summary: the ocular biometric parameters of the human crystalline lens including anterior chamber depth (acd), lens thickness (lt), radii of curvature of anterior and posterior lens (alr and plr), lens equatorial diameter (led), and lens vault (lv), automatically quantified by the casia2 (ss-oct; tomey, nagoya, japan). images of iridocorneal angle were obtained using casia2 and the schlemm' s canal (sc) and trabecular meshwork (tm) were quantified manually. both cycloplegia and non-cycloplegia images were obtained.

healthy individuals aged between 6 and 90 years, without history of ocular disease (except age-related cataract and/or myopia), were consecutively included from april to may 2019. all participants underwent visual acuity, dry and wet refraction, anterior and posterior segment examination, intraocular pressure (iop), and axial length (al) using iol-master 700 (carl zeiss meditec ag). investigators recruited children under 18 years old at a refraction outpatient clinic, who were prescribed cyclopentolate hydrochloride eyedrops (s.a. alcon-couvreur n.v., belguim) for cycloplegic refraction. for adults, they were prescribed compound tropicamide eyedrops (mydrin-p, santen pharmaceutical co., ltd, osaka, japan), consisting of 0.5% tropicamide mixed with 0.5% phenylephrine hydrochloride, for pupillary dilation in order to perform fundus examination at an outpatient clinic. exclusion criteria were as follow:ocular diseases other than cataracts; history of eye surgeries or injuries; shallow anterior chamber with a risk of angle closure. the data from right eye was selected for analysis.

Eligibility criteria:
inclusion criteria: healthy individuals aged between 6 and 90 years, without history of ocular disease (except age-related cataract and/or myopia) must be able to cooperate examination exclusion criteria: ocular diseases other than cataracts history of eye surgeries or injuries shallow anterior chamber with a risk of angle closure

Keywords: radius of curvature lens thickness equatorial diameter lens vault cycloplegia swept-source optical coherence tomography schlemm' s canal trabecular meshwork
surveillance study - incidence of antibiotic resistance in serial gram-negative bloodstream isolates

Conditions: Gram-negative Bacterial Infections

Summary: this research is important because it allows for the determination of resistance rates to antibiotics that may not be frequently tested by the clinical microbiology laboratory at university of pittsburgh medical center (upmc)-presbyterian. it also will provide antibiotic minimum inhibitory concentrations (mics) for these pathogens which may help in identifying the best empiric antibiotic option for gram-negative blood stream infections based on known pharmacodynamic parameters.

bacterial cultures will be ordered in the normal clinical course of the management of patients in the liver transplant icu by the medical team. these cultures are then processed by the clinical microbiology laboratory in the normal manner. if these cultures grow a gram-negative bacteria, they are eligible for this study. typically the clinical microbiology laboratory saves these bacteria for a period of time after the final microbiology report. at this time, unless asked otherwise, the bacteria will be placed in biohazardous waste containers for proper disposal. if these cultures have grown a gram-negative bacteria, they are eligible for this study, and will not be disposed of but will be given to the investigators without identifiers for this study. the antibiotic susceptibility of these organisms will be tested by the investigators in a separate research laboratory. mechanisms of antibiotic resistance may also be assessed.

Eligibility criteria:
inclusion criteria: * patients with positive gram-negative bacteria exclusion criteria: * less than 18 years of age

Keywords: gram negative bacteria culture infection